Dermata Therapeutics, Inc. (DRMA)
DRMA Stock Price Chart
Explore Dermata Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze DRMA price movements and trends.
DRMA Company Profile
Discover essential business fundamentals and corporate details for Dermata Therapeutics, Inc. (DRMA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
13 Aug 2021
Employees
8.00
Website
https://www.dermatarx.comCEO
Gerald T. Proehl
Description
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
DRMA Financial Timeline
Browse a chronological timeline of Dermata Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 13 Aug 2025
EPS came in at -$1.66 surpassing the estimated -$2.90 by +42.76%.
Stock split effective on 1 Aug 2025
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 May 2025
EPS came in at -$4.50 falling short of the estimated -$0.45 by -900.00%.
Earnings released on 17 Mar 2025
EPS came in at -$3.15 falling short of the estimated -$1.50 by -110.00%.
Earnings released on 13 Nov 2024
EPS came in at -$2.04 surpassing the estimated -$2.64 by +22.73%.
Earnings released on 7 Aug 2024
EPS came in at -$4.18 falling short of the estimated -$3.79 by -10.29%.
Stock split effective on 16 May 2024
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 May 2024
EPS came in at -$7.05 falling short of the estimated -$5.40 by -30.56%.
Earnings released on 21 Mar 2024
EPS came in at -$3.15 falling short of the estimated -$0.78 by -303.85%.
Earnings released on 9 Nov 2023
EPS came in at -$8.10 falling short of the estimated -$0.63 by -1.19K%.
Earnings released on 10 Aug 2023
EPS came in at -$9.45 falling short of the estimated -$0.92 by -927.17%.
Earnings released on 11 May 2023
EPS came in at -$34.03 falling short of the estimated -$2.65 by -1.18K%.
Stock split effective on 14 Mar 2023
Shares were split 1 : 16 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 21 Feb 2023
EPS came in at -$28.79 falling short of the estimated $3.20 by -999.69%.
Earnings released on 10 Nov 2022
EPS came in at -$47.98 falling short of the estimated -$3.52 by -1.26K%.
Earnings released on 15 Aug 2022
EPS came in at -$57.57 falling short of the estimated -$5.12 by -1.02K%.
Earnings released on 16 May 2022
EPS came in at -$79.16 falling short of the estimated -$6.40 by -1.14K%.
Earnings released on 28 Mar 2022
EPS came in at -$4.16 surpassing the estimated -$5.68 by +26.76%.
Earnings released on 15 Nov 2021
EPS came in at -$13.76 falling short of the estimated -$7.36 by -86.96%.
Earnings released on 27 Sept 2021
EPS came in at -$11.20 surpassing the estimated -$22.56 by +50.35%.
Earnings released on 16 Aug 2021
EPS came in at -$4.43 .
Earnings released on 31 Dec 2020
EPS came in at -$0.05 .
Earnings released on 30 Sept 2020
EPS came in at -$1.15 .
DRMA Stock Performance
Access detailed DRMA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.